Novel USP7 inhibitors demonstrate potent anti-cancer activity in models of AML, synergy with BCL2 inhibition, and a differentiated mechanism of action
Futran, A.S., Lu, T., Amberg-Johnson, K., Xu, J., Yang, X., He, S., Boyce, S., Bell, J., Pelletier, R., Suzuki, T., Huang, X., Qian, H., Fang, L., Xing, L., Xu, Z., Kurtz, S.E., Tyner, J.W., Tang, W., Guo, T., Akinsanya, K., Madge, D., Jensen, K.To be published.